Regency Centers is a preeminent national owner, operator, and developer of shopping centers located in suburban trade areas with compelling demographics. Our portfolio includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers. Operating as a fully integrated real estate company, Regency Centers is a qualified real estate investment trust (REIT) that is self-administered, self-managed, and an S&P 500 Index member.

Regency Centers Corporation

The latest announcement is out from Regis Healthcare Ltd. ( ($AU:REG) ). Regis Healthcare Ltd has reported a change in director Sally Margaret Free...

Regis Healthcare Director Sally Freeman Increases Shareholding

RBC Capital analyst Craig Wong-Pan downgraded Regis Healthcare Ltd. to a Hold yesterday and set a price target of A$5.00. Wong-Pan covers the Healt...

RBC Capital downgrades Regis Healthcare Ltd. (REG) to a Hold

In a report released today, from Macquarie maintained a Buy rating on Regis Healthcare Ltd., with a price target of A$5.90. In addition to Macquari...

Regis Healthcare Ltd. (REG) Receives a Buy from Macquarie

Regis Healthcare Ltd. received a Hold rating and a A$6.00 price target from Ord Minnett analyst Tom Godfrey today. Godfrey covers the Healthcare se...

Ord Minnett downgrades Regis Healthcare Ltd. (REG) to a Hold

In a report released today, David Low from UBS maintained a Hold rating on Regis Healthcare Ltd., with a price target of A$5.95. Low covers the Hea...

UBS Sticks to Its Hold Rating for Regis Healthcare Ltd. (REG)

The latest update is out from RemeGen Co. Ltd. Class H ( ($HK:9995) ). RemeGen Co., Ltd., a PRC-based biopharmaceutical company listed in Hong Kong...

RemeGen Deploys Idle Funds Into Discloseable Wealth Management Products

Regis Healthcare Ltd. ( ($AU:REG) ) has issued an announcement. Regis Healthcare Ltd has disclosed a change in the shareholding of director Carmel ...

Regis Healthcare Director Increases Shareholding via On‑Market Trade

Eregli Demir Ve Celik Fabrikalari T.A.S. ( ($TR:EREGL) ) has issued an announcement. Ereğli Demir ve Çelik Fabrikaları T.A.Ş. has notified the Cent...

Ereğli Iron and Steel Notifies Market of Share Conversion to Tradable Stock

Morgan Stanley analyst maintained a Hold rating on RemeGen Co. Ltd. Class H on August 25 and set a price target of HK$98.00. The company’s shares c...

Morgan Stanley Sticks to Their Hold Rating for RemeGen Co. Ltd. Class H (9995)

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The study titled “A Randomized, Double-blin...

Regeneron and Sanofi Advance IL-33 Strategy With Completed Rhinosinusitis Trial

In a report released today, Tom Godfrey from Ord Minnett maintained a Buy rating on Regis Healthcare Ltd., with a price target of A$8.40. According...

Regis Healthcare Ltd. (REG) Gets a Buy from Ord Minnett

In a report released today, Steven Wheen from Jarden maintained a Hold rating on Regis Healthcare Ltd., with a price target of A$7.50. Wheen covers...

Regis Healthcare Ltd. (REG) Gets a Hold from Jarden

An announcement from Regis Healthcare Ltd. ( ($AU:REG) ) is now available. Regis Healthcare has scheduled its 2026 Annual General Meeting for Tuesd...

Regis Healthcare Sets 2026 AGM Date and Director Nomination Deadline

Regis Healthcare Ltd. ( ($AU:REG) ) has provided an announcement. Regis Healthcare Limited has lodged its corporate governance statement for the ye...

Regis Healthcare Files Updated ASX Corporate Governance Statement

Regis Healthcare Ltd. ( ($AU:REG) ) just unveiled an announcement. Regis Healthcare reported a strong FY26, with revenue from services rising 16% t...

Regis Healthcare Delivers Strong FY26 Results and Expands Aged Care Portfolio

A class action lawsuit was filed against biotechnology company Regeneron ($REGN) on July 16, which could put further pressure on its troubled share...

Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. The Phase 2 study A Phase 2, Randomized, Placebo-Controlled ...

Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside

An update from TAV Havalimanlari Holding AS ( ($TAVHF) ) is now available. A disclosure from the Central Dematerialised System lists multiple Turki...

TAV Havalimanları Shares Among Blocks Converted to Tradable Stock on Borsa İstanbul

RemeGen Co. Ltd. Class H ( ($HK:9995) ) has shared an announcement. RemeGen Co., Ltd., a PRC-based biopharmaceutical company listed in Hong Kong, d...

RemeGen Commits US$100 Million of Idle Funds to OCBC Wealth Products in Discloseable Transaction

In a report released today, Richard Hightower from Barclays maintained a Buy rating on Regency Centers, with a price target of $92.00. According to...

Barclays Reaffirms Their Buy Rating on Regency Centers (REG)

U.S. stocks ended another positive week near record highs, although Friday’s weak retail sales report took some of the shine off the rally. The S&P...

The Week That Was, The Week Ahead: Macro and Markets, August 16

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is running a late-stage study on n...

Regeneron Targets Cat Allergy Eye Relief With New Phase 3 Antibody Trial

In a report released on August 6, Yang Huang from J.P. Morgan maintained a Buy rating on RemeGen Co. Ltd. Class H, with a price target of HK$129.00...

J.P. Morgan Reaffirms Their Buy Rating on RemeGen Co. Ltd. Class H (9995)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. The phase 1/2 study titled “REGN15505 Alone or in Combinatio...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REG	$75.26	-0.87%	884.12K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REG	$75.26	-0.9%	884.12K
3
4
5
6

REG

Get Regency Centers Corporation Data in Excel

Get Regency Centers Corporation Data in Excel